Altimmune Inc. (NASDAQ: ALT) Stock News & Analysis
Altimmune Inc. (NASDAQ: ALT) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 1 article on ALT since Wednesday, August 12, 2026, most recently "Altimmune (NASDAQ: ALT) Posts Q2 2026 Results With $519M Cash as Pemvidutide Advances Across Three Liver Disease Trials" on Wednesday, August 12, 2026. Coverage to date spans Earnings Report, tracking ALT's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
ALT Coverage -- 1 Article
Altimmune (NASDAQ: ALT) Posts Q2 2026 Results With $519M Cash as Pemvidutide Advances Across Three Liver Disease Trials
ALT beat Q2 EPS by $0.02, but the real story is $519M in cash and three concurrent pemvidutide trials now in motion across MASH, AUD, and ALD.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.